{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:58:02Z","timestamp":1790708282288,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Quebec Network on Suicide"},{"name":"Mood Disorders and Related Disorders"},{"name":"Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al Research Centre"},{"DOI":"10.13039\/501100024491","name":"Institut Universitaire sur les D\u00e9pendances","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023221","name":"Gaulin Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023221","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010523","name":"The Centre for Addiction and Mental Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010523","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Waypoint Centre for Mental Health Care"},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Health Research BC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"name":"St. Paul\u2019s Foundation Scholar Award"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CIS-144301, CIS-144302, CIS-144303, CIS-144304"],"award-info":[{"award-number":["CIS-144301, CIS-144302, CIS-144303, CIS-144304"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Traditional treatment approaches for prescription-type opioid use disorder (POUD), centered on abstinence, have limitations and hinder the development of interventions that meet the needs of people with POUD. Reduction in use without complete abstinence presents a promising avenue for intervention enhancement, but supporting data is scarce regarding its translation into positive patient outcomes. This study explores whether reducing opioid use frequency (OUF) during opioid agonist treatment correlates with reduced potential life problems in individuals with POUD, including those using fentanyl.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study is an exploratory analysis of the OPTIMA trial, a pragmatic, open-label, randomized controlled study comparing the effectiveness of flexible take-home dosing of buprenorphine\/naloxone and supervised methadone in reducing opioid use amongst individuals with POUD. OUF was assessed every two weeks for 24 weeks after treatment initiation using the Timeline Followback. Potential life problems were evaluated at baseline and study completion using the Addiction Severity Index Self-Report. The 114 participants who completed both baseline and end-of-study questionnaires were included. A repeated-measures generalized linear mixed model (GLMM) was used to evaluate the influence of OUF on potential life problems.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Reducing OUF was significantly associated with fewer problems related to medical status (<jats:italic>p<\/jats:italic>\u2009=\u20090.049), psychiatric status (<jats:italic>p<\/jats:italic>\u2009=\u20090.019), and alcohol problem severity (<jats:italic>p<\/jats:italic>\u2009=\u20090.001). The interaction was non-significant for employment (<jats:italic>p<\/jats:italic>\u2009=\u20090.264), family status (<jats:italic>p<\/jats:italic>\u2009=\u20090.352) and legal status (<jats:italic>p<\/jats:italic>\u2009=\u20090.050). Life improvements emerged with \u2264\u200921 days of opioid use per 28-day period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Findings underscore the significance of harm reduction goals focusing on opioid use reduction, which translated in improvements across many life domains.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>Study was registered with ClinicalTrials.gov (NCT03033732) prior to participant enrollment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12954-025-01157-4","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T06:46:41Z","timestamp":1738997201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study"],"prefix":"10.1186","volume":"22","author":[{"given":"Anne","family":"Bouthillier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Bastien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"McAnulty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamzah","family":"Bakouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Le Foll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Eugenia","family":"Socias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Jutras-Aswad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"1157_CR1","unstructured":"FDA. Timeline of Selected FDA Activities and Significant Events Addressing Substance Use and Overdose Prevention. 2023. Available from: https:\/\/www.fda.gov\/drugs\/information-drug-class\/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose"},{"key":"1157_CR2","unstructured":"Meier B. Pain killer: an empire of deceit and the origin of America\u2019s opioid epidemic. Random House; 2018."},{"key":"1157_CR3","unstructured":"Center for Disease Control and Prevention NCfHS. Wide-ranging online data for epidemiologic research (WONDER) 2022. Available from: http:\/\/wonder.cdc.gov"},{"key":"1157_CR4","doi-asserted-by":"crossref","unstructured":"Hedegaard H, Mini\u00f1o AM, Spencer MR, Warner M. Drug overdose deaths in the United States, 1999\u20132020. 2021.","DOI":"10.15620\/cdc:112340"},{"key":"1157_CR5","doi-asserted-by":"publisher","first-page":"108350","DOI":"10.1016\/j.drugalcdep.2020.108350","volume":"218","author":"C Florence","year":"2021","unstructured":"Florence C, Luo F, Rice K. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2021;218:108350.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"1157_CR6","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/ajad.12188","volume":"24","author":"ML Griffin","year":"2015","unstructured":"Griffin ML, Bennett HE, Fitzmaurice GM, Hill KP, Provost SE, Weiss RD. Health-related quality of life among prescription opioid\u2010dependent patients: results from a multi\u2010site study. Am J Addictions. 2015;24(4):308\u201314.","journal-title":"Am J Addictions"},{"key":"1157_CR7","doi-asserted-by":"crossref","unstructured":"Tun S, Balasingam V, Singh DS. Factors Affecting Addiction Severity Index (ASI) among Clients Enrolled in Methadone Maintenance Treatment (MMT) Program in Myanmar. 2021.","DOI":"10.21203\/rs.3.rs-151916\/v1"},{"issue":"10208","key":"1157_CR8","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","volume":"394","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BD, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560\u201379.","journal-title":"Lancet"},{"issue":"2S","key":"1157_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADM.0000000000000633","volume":"14","author":"C Cunningham","year":"2020","unstructured":"Cunningham C, Edlund MJ, Fishman M, Gordon AJ, Jones HE, Langleben D, et al. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med. 2020;14(2S):1\u201391.","journal-title":"J Addict Med"},{"key":"1157_CR10","doi-asserted-by":"crossref","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357.","DOI":"10.1136\/bmj.j1550"},{"issue":"5","key":"1157_CR11","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1111\/add.15739","volume":"117","author":"O Rogeberg","year":"2022","unstructured":"Rogeberg O, Bergsvik D, Clausen T. Opioid overdose deaths and the expansion of opioid agonist treatment: a population-based prospective cohort study. Addiction. 2022;117(5):1363\u201371.","journal-title":"Addiction"},{"issue":"3","key":"1157_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0376-8716(01)00171-5","volume":"65","author":"M Farr\u00e9","year":"2002","unstructured":"Farr\u00e9 M, Mas A, Torrens M, Moreno Vc, Cam\u0131\u0301 J. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend. 2002;65(3):283\u201390.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1157_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/08897077.2011.616816","volume":"33","author":"J Gryczynski","year":"2012","unstructured":"Gryczynski J, Kinlock TW, Kelly SM, O\u2019Grady KE, Gordon MS, Schwartz RP. Opioid agonist maintenance for probationers: patient-level predictors of treatment retention, drug use, and crime. Substance Abuse. 2012;33(1):30\u20139.","journal-title":"Substance Abuse"},{"issue":"9","key":"1157_CR14","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1111\/j.1360-0443.2008.02249.x","volume":"103","author":"P Lawrinson","year":"2008","unstructured":"Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV\/AIDS. Addiction. 2008;103(9):1484\u201392.","journal-title":"Addiction"},{"issue":"8","key":"1157_CR15","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/cid\/ciw416","volume":"63","author":"AJ Low","year":"2016","unstructured":"Low AJ, Mburu G, Welton NJ, May MT, Davies CF, French C, et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. Clin Infect Dis. 2016;63(8):1094\u2013104.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1157_CR16","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1360-0443.2004.00752.x","volume":"99","author":"C Godfrey","year":"2004","unstructured":"Godfrey C, Stewart D, Gossop M. Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). Addiction. 2004;99(6):697\u2013707.","journal-title":"Addiction"},{"key":"1157_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.drugalcdep.2013.10.011","volume":"134","author":"JP Feelemyer","year":"2014","unstructured":"Feelemyer JP, Des Jarlais DC, Arasteh K, Phillips BW, Hagan H. Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: an international systematic review. Drug Alcohol Depend. 2014;134:251\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"1157_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/add.13238","volume":"111","author":"YI Hser","year":"2016","unstructured":"Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, et al. Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi\u2010site trial. Addiction. 2016;111(4):695\u2013705.","journal-title":"Addiction"},{"issue":"2","key":"1157_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/02791072.2015.1014948","volume":"47","author":"SG Mitchell","year":"2015","unstructured":"Mitchell SG, Gryczynski J, Schwartz RP, Myers CP, O\u2019Grady KE, Olsen YK, et al. Changes in quality of life following buprenorphine treatment: relationship with treatment retention and illicit opioid use. J Psychoactive Drugs. 2015;47(2):149\u201357.","journal-title":"J Psychoactive Drugs"},{"issue":"10","key":"1157_CR20","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1176\/appi.ajp.21090964","volume":"179","author":"D Jutras-Aswad","year":"2022","unstructured":"Jutras-Aswad D, Le Foll B, Ahamad K, Lim R, Bruneau J, Fischer B, et al. Flexible buprenorphine\/naloxone model of care for reducing opioid use in individuals with prescription-type opioid use disorder: an open-label, pragmatic, noninferiority randomized controlled trial. Am J Psychiatry. 2022;179(10):726\u201339.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1157_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1176\/appi.ajp.2019.19121284","volume":"177","author":"ND Volkow","year":"2020","unstructured":"Volkow ND. Personalizing the treatment of substance use disorders. Am J Psychiatry. 2020;177(2):113\u20136.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1157_CR22","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/npp.2011.84","volume":"37","author":"ND Volkow","year":"2012","unstructured":"Volkow ND, Skolnick P. New medications for substance use disorders: challenges and opportunities. Neuropsychopharmacology. 2012;37(1):290\u20132.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1157_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/10550880802122554","volume":"27","author":"Y-I Hser","year":"2008","unstructured":"Hser Y-I, Huang D, Brecht M-L, Li L, Evans E. Contrasting trajectories of heroin, cocaine, and methamphetamine use. J Addict Dis. 2008;27(3):13\u201321.","journal-title":"J Addict Dis"},{"key":"1157_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF03391707","volume":"35","author":"AT McLellan","year":"2013","unstructured":"McLellan AT, Starrels JL, Tai B, Gordon AJ, Brown R, Ghitza U, et al. Can substance use disorders be managed using the chronic care model? Review and recommendations from a NIDA consensus group. Public Health Rev. 2013;35:1\u201314.","journal-title":"Public Health Rev"},{"key":"1157_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.drugalcdep.2017.05.049","volume":"179","author":"P Alves","year":"2017","unstructured":"Alves P, Sales C, Ashworth M. Does outcome measurement of treatment for substance use disorder reflect the personal concerns of patients? A scoping review of measures recommended in Europe. Drug Alcohol Depend. 2017;179:299\u2013308.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1157_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","volume":"6","author":"J Strang","year":"2020","unstructured":"Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, et al. Opioid use disorder. Nat Reviews Disease Primers. 2020;6(1):3.","journal-title":"Nat Reviews Disease Primers"},{"issue":"3","key":"1157_CR27","first-page":"235","volume":"88","author":"KF Hawk","year":"2015","unstructured":"Hawk KF, Vaca FE, D\u2019Onofrio G, Focus. Addiction: reducing fatal opioid overdose: Prevention, treatment and harm reduction strategies. Yale J Biol Med. 2015;88(3):235.","journal-title":"Yale J Biol Med"},{"issue":"2","key":"1157_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/08897077.2019.1671940","volume":"41","author":"EL Davis","year":"2020","unstructured":"Davis EL, Kelly PJ, Deane FP, Baker AL, Buckingham M, Degan T, et al. The relationship between patient-centered care and outcomes in specialist drug and alcohol treatment: a systematic literature review. Substance Abuse. 2020;41(2):216\u201331.","journal-title":"Substance Abuse"},{"key":"1157_CR29","unstructured":"FDA. Opioid use disorder: Endpoints for demonstrating effectiveness of drugs for medication-assisted treatment guidance for industry. (2018). US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM615743.pdf. 2020."},{"key":"1157_CR30","unstructured":"Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioid-and stimulant-related harms in Canada. Public Health Agency of Canada Ottawa; 2021."},{"issue":"1","key":"1157_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41398-019-0625-0","volume":"9","author":"Y Han","year":"2019","unstructured":"Han Y, Yan W, Zheng Y, Khan MZ, Yuan K, Lu L. The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies. Translational Psychiatry. 2019;9(1):282.","journal-title":"Translational Psychiatry"},{"key":"1157_CR32","unstructured":"Government of Canada. Opioid-and stimulant-related harms in Canada. 2021."},{"key":"1157_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cct.2018.04.001","volume":"69","author":"ME Socias","year":"2018","unstructured":"Socias ME, Ahamad K, Le Foll B, Lim R, Bruneau J, Fischer B, et al. The OPTIMA study, buprenorphine\/naloxone and methadone models of care for the treatment of prescription opioid use disorder: study design and rationale. Contemp Clin Trials. 2018;69:21\u20137.","journal-title":"Contemp Clin Trials"},{"key":"1157_CR34","volume-title":"A comparison of a self-administered ASI with the standard ASI interview","author":"J Cacciola","year":"1998","unstructured":"Cacciola J, McLellan A, Alterman A, Mulvaney F. A comparison of a self-administered ASI with the standard ASI interview. Problems of Drug Dependence Rockville, MD: National Institutes of Health; 1998."},{"issue":"3","key":"1157_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0740-5472(01)00161-1","volume":"20","author":"D Carise","year":"2001","unstructured":"Carise D, McLellan AT, Cacciola J, Love M, Cook T, Bovasso G, et al. Suggested specifications for a standardized addiction Severity Index database. J Subst Abuse Treat. 2001;20(3):239\u201344.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"1157_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/08039488.2019.1666300","volume":"74","author":"H Ljungvall","year":"2020","unstructured":"Ljungvall H, Persson A, \u00c5senl\u00f6f P, Heilig M, Ekselius L. Reliability of the Addiction Severity Index self-report form (ASI-SR): a self-administered questionnaire based on the Addiction Severity Index composite score domains. Nord J Psychiatry. 2020;74(1):9\u201315.","journal-title":"Nord J Psychiatry"},{"key":"1157_CR37","doi-asserted-by":"publisher","first-page":"108000","DOI":"10.1016\/j.jsat.2020.108000","volume":"113","author":"D Eddie","year":"2020","unstructured":"Eddie D, Vilsaint CL, Hoffman LA, Bergman BG, Kelly JF, Hoeppner BB. From working on recovery to working in recovery: employment status among a nationally representative US sample of individuals who have resolved a significant alcohol or other drug problem. J Subst Abuse Treat. 2020;113:108000.","journal-title":"J Subst Abuse Treat"},{"key":"1157_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jsat.2019.09.002","volume":"106","author":"AQ Miguel","year":"2019","unstructured":"Miguel AQ, Kiluk BD, Roos CR, Babuscio TA, Nich C, Mari JJ, et al. Change in employment status and cocaine use treatment outcomes: a secondary analysis across six clinical trials. J Subst Abuse Treat. 2019;106:89\u201396.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"1157_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0740-5472(03)00130-2","volume":"25","author":"RL Hubbard","year":"2003","unstructured":"Hubbard RL, Craddock SG, Anderson J. Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). J Subst Abuse Treat. 2003;25(3):125\u201334.","journal-title":"J Subst Abuse Treat"},{"key":"1157_CR40","unstructured":"Identifying Barriers to Employment After Substance Use Disorder Treatment. Just Overturn Barriers (JOBs) Project 2022."},{"issue":"12","key":"1157_CR41","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Global Health. 2017;5(12):e1192\u2013207.","journal-title":"Lancet Global Health"},{"issue":"1","key":"1157_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-021-00535-y","volume":"18","author":"D Frank","year":"2021","unstructured":"Frank D, Mateu-Gelabert P, Perlman DC, Walters SM, Curran L, Guarino H. It\u2019s like \u2018liquid handcuffs: the effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives. Harm Reduct J. 2021;18(1):1\u201310.","journal-title":"Harm Reduct J"},{"key":"1157_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.drugalcdep.2016.11.029","volume":"171","author":"S Larney","year":"2017","unstructured":"Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend. 2017;171:39\u201349.","journal-title":"Drug Alcohol Depend"},{"key":"1157_CR44","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40263-019-00660-0","volume":"33","author":"S Mercadante","year":"2019","unstructured":"Mercadante S, Arcuri E, Santoni A. Opioid-induced tolerance and hyperalgesia. CNS Drugs. 2019;33:943\u201355.","journal-title":"CNS Drugs"},{"issue":"2","key":"1157_CR45","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","volume":"35","author":"DR Wesson","year":"2003","unstructured":"Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs. 2003;35(2):253\u20139.","journal-title":"J Psychoactive Drugs"},{"issue":"17\u201318","key":"1157_CR46","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1503\/cmaj.160290","volume":"188","author":"JH Donroe","year":"2016","unstructured":"Donroe JH, Holt SR, Tetrault JM. Caring for patients with opioid use disorder in the hospital. CMAJ. 2016;188(17\u201318):1232\u20139.","journal-title":"CMAJ"},{"issue":"3","key":"1157_CR47","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1521-0391.2012.12008.x","volume":"22","author":"DF Gros","year":"2013","unstructured":"Gros DF, Milanak ME, Brady KT, Back SE. Frequency and severity of comorbid mood and anxiety disorders in prescription opioid dependence. Am J Addictions. 2013;22(3):261\u20135.","journal-title":"Am J Addictions"},{"issue":"4","key":"1157_CR48","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41380-018-0117-2","volume":"24","author":"M Peci\u00f1a","year":"2019","unstructured":"Peci\u00f1a M, Karp JF, Mathew S, Todtenkopf MS, Ehrich EW, Zubieta J-K. Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Mol Psychiatry. 2019;24(4):576\u201387.","journal-title":"Mol Psychiatry"},{"issue":"4","key":"1157_CR49","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3122\/jabfm.2017.04.170112","volume":"30","author":"MA Davis","year":"2017","unstructured":"Davis MA, Lin LA, Liu H, Sites BD. Prescription opioid use among adults with mental health disorders in the United States. J Am Board Family Med. 2017;30(4):407\u201317.","journal-title":"J Am Board Family Med"},{"issue":"1\u20133","key":"1157_CR50","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pain.2005.09.020","volume":"119","author":"MD Sullivan","year":"2005","unstructured":"Sullivan MD, Edlund MJ, Steffick D, Un\u00fctzer J. Regular use of prescribed opioids: association with common psychiatric disorders. Pain. 2005;119(1\u20133):95\u2013103.","journal-title":"Pain"},{"issue":"1\u20133","key":"1157_CR51","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.drugalcdep.2011.07.002","volume":"120","author":"TS Schepis","year":"2012","unstructured":"Schepis TS, McCabe SE. Exploring age of onset as a causal link between major depression and nonmedical use of prescription medications. Drug Alcohol Depend. 2012;120(1\u20133):99\u2013104.","journal-title":"Drug Alcohol Depend"},{"key":"1157_CR52","doi-asserted-by":"crossref","unstructured":"Schepis TS, McCabe SEJTJ. Prescription opioid misuse in us older adults: associated comorbidities and reduced quality of life in the National Epidemiologic Survey of Alcohol and related Conditions-III. 2019;80(6):13246.","DOI":"10.4088\/JCP.19m12853"},{"issue":"3","key":"1157_CR53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.tins.2012.11.002","volume":"36","author":"P-E Lutz","year":"2013","unstructured":"Lutz P-E, Kieffer BL. Opioid receptors: distinct roles in mood disorders. Trends Neurosci. 2013;36(3):195\u2013206.","journal-title":"Trends Neurosci"},{"issue":"8","key":"1157_CR54","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1177\/07067437221145013","volume":"68","author":"G Bastien","year":"2023","unstructured":"Bastien G, McAnulty C, Ledjiar O, Socias ME, Le Foll B, Lim R, et al. Effects of Buprenorphine\/Naloxone and Methadone on depressive symptoms in people with prescription opioid use disorder: a pragmatic Randomised Controlled Trial. Can J Psychiatry. 2023;68(8):572\u201385.","journal-title":"Can J Psychiatry"},{"key":"1157_CR55","unstructured":"Huang W, Penaherrera EP, Desir DF, Gamarro DL, Cottrell J, Chu T et al. Bi-directional Acceleration of Alcohol Use and Opioid Use Disorder. Journal of drug and alcohol research. 2019;2019."},{"key":"1157_CR56","doi-asserted-by":"crossref","unstructured":"Le A, Khanna J, Kalant H, LeBlanc A. Cross-tolerance between ethanol and morphine. Alcohol Aldehyde Metabolizing Systems-IV. 1980:771\u20137.","DOI":"10.1007\/978-1-4757-1419-7_80"},{"issue":"3","key":"1157_CR57","doi-asserted-by":"publisher","first-page":"e0171275","DOI":"10.1371\/journal.pone.0171275","volume":"12","author":"S-C Kao","year":"2017","unstructured":"Kao S-C, Tsai H-I, Cheng C-W, Lin T-W, Chen C-C, Lin C-S. The association between frequent alcohol drinking and opioid consumption after abdominal surgery: a retrospective analysis. PLoS ONE. 2017;12(3):e0171275.","journal-title":"PLoS ONE"},{"issue":"4","key":"1157_CR58","doi-asserted-by":"publisher","first-page":"431","DOI":"10.15288\/jsad.2019.80.431","volume":"80","author":"CR Roos","year":"2019","unstructured":"Roos CR, Nich C, Mun CJ, Mendonca J, Babuscio TA, Witkiewitz K, et al. Patterns of cocaine use during treatment: associations with baseline characteristics and follow-up functioning. J Stud Alcohol Drug. 2019;80(4):431\u201340.","journal-title":"J Stud Alcohol Drug"},{"key":"1157_CR59","unstructured":"FDA. Alcoholism: developing drugs for treatment. Center for Drug Evaluation and Research (CDER). 2015."},{"issue":"1","key":"1157_CR60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.15288\/jsad.2017.78.59","volume":"78","author":"K Witkiewitz","year":"2017","unstructured":"Witkiewitz K, Roos CR, Pearson MR, Hallgren KA, Maisto SA, Kirouac M, et al. How much is too much? Patterns of drinking during alcohol treatment and associations with post-treatment outcomes across three alcohol clinical trials. J Stud Alcohol Drug. 2017;78(1):59\u201369.","journal-title":"J Stud Alcohol Drug"},{"issue":"3","key":"1157_CR61","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1530-0277.2007.00595.x","volume":"32","author":"RA Breslow","year":"2008","unstructured":"Breslow RA, Graubard BI. Prospective study of alcohol consumption in the United States: quantity, frequency, and cause-specific mortality. Alcoholism: Clin Experimental Res. 2008;32(3):513\u201321.","journal-title":"Alcoholism: Clin Experimental Res"},{"key":"1157_CR62","doi-asserted-by":"crossref","unstructured":"Dawson DA, Goldstein RB, Grant BF. Rates and correlates of relapse among individuals in remission from DSM-IV alcohol dependence: a 3\u2010year follow\u2010up. Alcoholism: Clinical and Experimental Research. 2007;31(12):2036-45.","DOI":"10.1111\/j.1530-0277.2007.00536.x"},{"issue":"12","key":"1157_CR63","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1111\/j.1530-0277.2010.01290.x","volume":"34","author":"D Falk","year":"2010","unstructured":"Falk D, Wang XQ, Liu L, Fertig J, Mattson M, Ryan M, et al. Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcoholclinical trials. Alcoholism: Clin Experimental Res. 2010;34(12):2022\u201334.","journal-title":"Alcoholism: Clin Experimental Res"},{"issue":"4","key":"1157_CR64","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1360-0443.2003.00665.x","volume":"99","author":"K M\u00e4kel\u00e4","year":"2004","unstructured":"M\u00e4kel\u00e4 K. Studies of the reliability and validity of the Addiction Severity Index. Addiction. 2004;99(4):398\u2013410.","journal-title":"Addiction"},{"key":"1157_CR65","doi-asserted-by":"publisher","first-page":"109070","DOI":"10.1016\/j.drugalcdep.2021.109070","volume":"228","author":"BD Kiluk","year":"2021","unstructured":"Kiluk BD, Roos CR, Aslan M, Gueorguieva R, Nich C, Babuscio TA, et al. Detecting change in psychiatric functioning in clinical trials for cocaine use disorder: sensitivity of the addiction severity index and brief Symptom Inventory. Drug Alcohol Depend. 2021;228:109070.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"1157_CR66","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1213\/ANE.0000000000002565","volume":"125","author":"G Mahajan","year":"2017","unstructured":"Mahajan G. Role of urine drug testing in the current opioid epidemic. Anesth Analgesia. 2017;125(6):2094\u2013104.","journal-title":"Anesth Analgesia"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01157-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01157-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01157-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T07:32:56Z","timestamp":1738999976000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01157-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01157-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests\/personal relationships, none of these organizations were involved in this study.\u00a0BLF has obtained funding from Pfizer Inc., Indivior, Canopy Growth Corporation, Bioprojet Pharma, Alcohol Countermeasure Systems (ACS), Alkermes and Universal Ibogaine. Dr. Le Foll has in-kind donations of cannabis products from Aurora Cannabis Enterprises Inc. and study medication donations from Pfizer Inc. (varenicline for smoking cessation) and Bioprojet Pharma. He was also provided a coil for a Transcranial magnetic stimulation (TMS) study from Brainsway. BLF has received in kind donations of nabiximols from GW Pharmaceuticals for past studies funded by CIHR and NIH. He has participated in a session of a National Advisory Board Meeting (Emerging Trends BUP-XR) for Indivior Canada and is part of Steering Board for a clinical trial for Indivior. He has been consultant for Shinogi. He got travel support to attend an event by Bioprojet. MES received funding from Indivior Investigator Initiated program paid to her institution for work outside this study. DJA received study materials from Cardiol Therapeutics and Exka for clinical trials which is not related to the topic of the present manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}